Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Abstract: A vehicle control data generation method is provided. A self-driving mode of a vehicle automatically generates a command value of a propelling force produced by a propelling force generator independently of an accelerator operation. An execution device provides a greater reward based on an obtained state of the vehicle when a standard of a characteristic of the vehicle is met than when the standard is not met. Providing the reward changes a reward that is provided when the characteristic of the vehicle is a predetermined characteristic in the self-driving mode such that the changed reward differs from a reward that is provided when the characteristic of the vehicle is the predetermined characteristic in a manual driving mode.

Abstract: A method of generating vehicle control data includes: storing, with a storage device, relationship prescription data; operating, with an execution device, an operable portion of an internal combustion engine; acquiring, with the execution device, a detection value from a sensor that detects the state of the vehicle; calculating, with the execution device, a reward; and updating, with the execution device, the relationship prescription data using update mapping determined in advance, the update mapping using the state of the vehicle based on the detection value, an operation amount used to operate the operable portion, and the reward corresponding to the operation as arguments, and returning the relationship prescription data which have been updated such that an expected profit for the reward calculated when the operable portion is operated in accordance with the relationship prescription data increases.

Abstract: Provided is a method of generating vehicle control data. The method is applied to a vehicle configured to select one of a plurality of traveling control modes and is executed by a processor in a state in which relationship definition data defining a relationship between a state of the vehicle and an action variable as a variable relating to an operation of electronic equipment in the vehicle is stored in a memory. The method includes operation processing for operating the electronic equipment, acquisition processing for acquiring a detection value of a sensor configured to detect the state of the vehicle, reward calculation processing for providing reward, and update processing for updating the relationship definition data.

Abstract: A vehicle control data generation method includes causing processing circuitry to execute an obtaining process that obtains a state of a vehicle and a specifying variable, an operating process that operates an electronic device, a reward calculating process that provides a greater reward when a characteristic of the vehicle meets a standard than when the characteristic does not meet the standard, an updating process that updates relationship defining data. The update map outputs the updated relationship defining data so as to increase an expected return for the reward in a case where the electronic device is operated in accordance with the relationship defining data. The reward calculating process includes a changing process that changes the reward between when the characteristic of the vehicle is a predetermined characteristic in an EV mode and when the characteristic is the predetermined characteristic in a HV mode.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: This invention provides stable, highly crystalline forms of Complement factor D inhibitors Compound 1 and Compound 2 for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: A method of manufacturing a stacked core includes forming a first pilot hole in a metal plate, forming a worked portion of the metal plate in a state in which a first pilot pin is inserted into the first pilot hole, the worked portion being displaced relative to a plane of the metal plate, press-fitting the worked portion of the metal plate to reposition the worked portion to extend along the plane of the metal plate, forming a second pilot hole in the metal plate after press-fitting the worked portion of the metal plate, and forming a blanked member by blanking the metal plate in a state in which a second pilot pin is inserted into the second pilot hole, the blanked member including the worked portion.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: This invention provides stable, highly crystalline forms of Complement Factor D inhibitor Compound 3 for therapeutic applications.

Abstract: A method of manufacturing a laminated core includes supplying a stator material to a punching device and obtaining an electromagnetic steel plate corresponding to a rectangular processed body by punching the stator material. To obtain the electromagnetic steel plate ES, a slit is formed outside a processed body forming area in the stator material along a long side of the processed body forming area, and a center portion of the processed body forming area is punched out in a circular shape. Additionally, the processed body forming area is punched out after the slit is formed and the center portion is punched out. The laminated core is obtained by laminating and fastening a plurality of the electromagnetic steel plates.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, or a pharmaceutically acceptable salt or composition thereof. The inhibitors of Factor D described herein reduce the excessive activation of complement, and are useful to treat disorders mediated by the complement system.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.